Time to health-related quality of life improvement analysis was developed to enhance evaluation of modern anticancer therapies.
Adolescent
Adult
Aged
Aged, 80 and over
Female
Humans
Kaplan-Meier Estimate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Male
Middle Aged
Neoplasms
/ therapy
Progression-Free Survival
Proof of Concept Study
Proportional Hazards Models
Pyrimidines
/ administration & dosage
Quality Improvement
Quality of Life
Time Factors
Treatment Outcome
Young Adult
Cancer
Competing risks
Health-related quality of life
Immunotherapy
Targeted therapies
Time to HRQOL improvement
Time to sustained HRQOL improvement
Journal
Journal of clinical epidemiology
ISSN: 1878-5921
Titre abrégé: J Clin Epidemiol
Pays: United States
ID NLM: 8801383
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
11
11
2019
revised:
01
06
2020
accepted:
15
06
2020
pubmed:
21
6
2020
medline:
6
3
2021
entrez:
21
6
2020
Statut:
ppublish
Résumé
Major advances have recently been made in the treatments of cancer, which now also have the potential to improve patients' health-related quality of life (HRQOL). We propose the time to HRQOL improvement (TTI) and the time to sustained HRQOL improvement (TTSI) as potentially important cancer outcomes to be used in longitudinal HRQOL analyses. As proof of principle, we defined TTI and TTSI, using the Fine-Gray model to include competing risks in estimates, in a case study in real life of a cohort of newly diagnosed patients with cancer receiving a targeted therapy. HRQOL was evaluated before and during therapy with six assessments over a 24-month period, using the well-validated European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30. For each assessed HRQOL domain, we assessed TTI and TTSI and estimated the cumulative incidence of patients' clinically meaningful improvements, also accounting for the occurrence of competing events. TTI and TTSI are potentially important outcomes in the era of modern anticancer therapies. The analysis of TTI and TTSI by competing risks approach will further add to the statistical methods that can be used to inform on the impact of cancer therapies on patients' HRQOL.
Identifiants
pubmed: 32562837
pii: S0895-4356(19)31037-6
doi: 10.1016/j.jclinepi.2020.06.016
pii:
doi:
Substances chimiques
Pyrimidines
0
nilotinib
F41401512X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9-18Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.